Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.55
-3.8%		$0.43
$0.23
▼
$2.75
$10.66M17.25 million shs248,521 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.41
-4.9%		$0.59
$0.16
▼
$15.75
$8.07M2639,139 shs197,615 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.25
+2.0%		$2.32
$1.10
▼
$10.43
$1.98M0.76183,126 shs50,455 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$0.40
-2.0%		$0.54
$0.40
▼
$3.23
$6.18M1.521.00 million shs83,268 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+2.99%+33.20%+17.58%+96.47%-75.32%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+5.15%-2.31%-39.13%-81.16%-96.28%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-18.12%-15.86%-41.90%-75.00%-87.05%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-1.42%-21.13%-27.33%-37.33%-85.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.55
-3.8%		$0.43
$0.23
▼
$2.75
$10.66M17.25 million shs248,521 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.41
-4.9%		$0.59
$0.16
▼
$15.75
$8.07M2639,139 shs197,615 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.25
+2.0%		$2.32
$1.10
▼
$10.43
$1.98M0.76183,126 shs50,455 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$0.40
-2.0%		$0.54
$0.40
▼
$3.23
$6.18M1.521.00 million shs83,268 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
+2.99%+33.20%+17.58%+96.47%-75.32%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+5.15%-2.31%-39.13%-81.16%-96.28%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-18.12%-15.86%-41.90%-75.00%-87.05%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-1.42%-21.13%-27.33%-37.33%-85.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.33
Hold$3.00624.64% Upside
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
1.80
Reduce$1.00148.76% Upside

Current Analyst Ratings Breakdown

Latest SILO, MBRX, ENSC, and TRAW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$3.00
8/26/2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral$1.00
7/17/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
7/17/2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M2.11N/AN/A$0.63 per share0.87
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$4.69 per shareN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$70K28.28N/AN/A$7.10 per share0.18
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$2.79M2.21$0.74 per share0.54($0.07) per share-5.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$2.76N/AN/AN/A-280.53%-2,550.30%-320.49%11/13/2026 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$33.56M-$7.13N/AN/AN/AN/A-143.51%-24.53%11/12/2026 (Estimated)
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-81.75%-66.35%12/2/2026 (Estimated)
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$9.17M-$1.74N/AN/AN/AN/A-23,868.92%-165.52%11/12/2026 (Estimated)

Latest SILO, MBRX, ENSC, and TRAW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$0.3350-$0.16+$0.1750-$0.16N/AN/A
8/13/2026Q2 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.20-$0.20N/A-$0.20$1.20 million$1.16 million
8/13/2026Q2 2026
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$1.55-$1.40+$0.15-$1.40N/AN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.70
0.70
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
0.94
0.94
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
0.93
0.93

Institutional Ownership

CompanyInstitutional Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%

Insider Ownership

CompanyInsider Ownership
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
2.80%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
18.04%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1019.46 million18.91 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
1719.48 million15.96 millionNot Optionable
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
31.59 million1.53 millionNot Optionable
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
715.37 million14.21 millionNo Data

Recent News About These Companies

Head-To-Head Analysis: Traws Pharma (NASDAQ:TRAW) versus Jupiter Neurosciences (NASDAQ:JUNS)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084333
Traws Pharma shares rise after Q2 loss comes in better than expected
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/traws-pharma-shares-rise-q2-123132198.html
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345629/0/en/traws-pharma-reports-q2-2026-financial-results-and-provides-business-highlights.html
Traws Pharma Announces New At-The-Market Offering Program
July 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/traws-pharma-announces-new-at-the-market-offering-program?utm_source=marketbeat.com&utm_medium=referral
Traws Pharma Stock Dividends | NASDAQ:TRAW | Benzinga
July 8, 2026  |  benzinga.comhttps://www.benzinga.com/quote/TRAW/dividends
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315171/0/en/traws-pharma-provides-updated-guidance-on-influenza-prophylaxis-program.html
Outlook for Bucks County biotech take another hit with second setback for flu drug
June 15, 2026  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2026/06/15/traws-pharma-newtown-influenza-bird-flu-stock.html
Traws defers midphase flu study after negative regulatory review
June 15, 2026  |  fiercebiotech.comF
Micron, Nebius surge premarket; Traws Pharma tumbles
June 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/micron-nebius-surge-premarket-traws-115146985.html
Traws Pharma shares slide after UK regulator postpones influenza study
June 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/traws-pharma-shares-slide-after-uk-regulator-postpones-influenza-study/ar-AA25FClS
Why did TRAW stock slump 28% after hours?
June 13, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/why-did-traw-stock-slump-28-after-hours/ar-AA25w3pJ
Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review
June 12, 2026  |  quiverquant.comQ
Traws Pharma Provides Regulatory Update on Influenza Program
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311345/0/en/traws-pharma-provides-regulatory-update-on-influenza-program.html
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
May 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/27/3301975/0/en/traws-pharma-announces-antiviral-program-targeting-ongoing-hantavirus-and-ebola-virus-disease-outbreaks.html
Traws Pharma Updates ATM Equity Offering Prospectus Supplements
May 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/traws-pharma-updates-atm-equity-offering-prospectus-supplements?utm_source=marketbeat.com&utm_medium=referral
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295724/0/en/traws-pharma-provides-business-highlights-and-reports-q1-2026-financial-results.html
Traws Pops on Hantavirus Research
May 9, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23259/Traws-Pops-on-Hantavirus-Research
A hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gains
May 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/a-hantavirus-update-has-sent-this-nano-cap-biotech-stock-surging-today-here-s-why-retail-sees-potential-20x-gains/ar-AA22HxBr
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
May 8, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/05/52413763/traws-pharma-gains-after-hantavirus-drug-development-update-amid-cruise-ship-outbreak
Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment
May 8, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.55 -0.02 (-3.76%)
As of 02:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.41 -0.02 (-4.87%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$1.25 +0.03 (+2.05%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$0.40 -0.01 (-1.98%)
As of 02:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas